These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2945495)

  • 1. Natural killer cell activity and ultrastructure in myeloproliferative reactions in infants with Down's syndrome.
    Miale TD; Nasrallah AG; Lobel SA; Demian S; Bowman WP
    Am J Pediatr Hematol Oncol; 1986; 8(3):191-9. PubMed ID: 2945495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome.
    Hayashi Y; Eguchi M; Sugita K; Nakazawa S; Sato T; Kojima S; Bessho F; Konishi S; Inaba T; Hanada R
    Blood; 1988 Jul; 72(1):15-23. PubMed ID: 2968822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased natural killer cell activity in children with untreated acute leukemia.
    Nasrallah AG; Miale TD
    Cancer Res; 1983 Nov; 43(11):5580-5. PubMed ID: 6352019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia with Down's syndrome: translocation between chromosomes 1 and 19 in acute myelomonocytic leukemia following transient congenital myeloproliferative syndrome.
    Morgan R; Hecht F; Cleary ML; Sklar J; Link MP
    Blood; 1985 Dec; 66(6):1466-8. PubMed ID: 2415189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital leukaemia and the neonatal myeloproliferative disorders associated with Down's syndrome.
    Weinstein HJ
    Clin Haematol; 1978 Feb; 7(1):147-54. PubMed ID: 148990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transient myeloproliferation and acute myeloid leukemia in infants with Down's syndrome].
    Creutzig U; Ritter J; Vormoor J; Eschenbach C; Dickerhoff R; Burdach S; Scheel-Walter HG; Kühl J; Schellong G
    Klin Padiatr; 1990; 202(4):253-7. PubMed ID: 2144325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematological changes in Down's syndrome.
    Ganick DJ
    Crit Rev Oncol Hematol; 1986; 6(1):55-69. PubMed ID: 2946491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congenital transient myeloproliferative disorder progressing to acute myeloid leukemia in Down's syndrome: a case report.
    Prabhu PD; V G; Niveditha SR; Gayathri BR; Keshavamurthy SR
    Indian J Pathol Microbiol; 2004 Jan; 47(1):48-50. PubMed ID: 15471129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal myeloproliferative disorders in Down's syndrome and congenital leukemias.
    Paolucci G; Rosito P
    Haematologica; 1987; 72(6 Suppl):121-5. PubMed ID: 2965083
    [No Abstract]   [Full Text] [Related]  

  • 10. Leucocyte function in Down's syndrome and acute leukaemia.
    Gregory L; Williams R; Thompson E
    Lancet; 1972 Jun; 1(7765):1359-61. PubMed ID: 4113564
    [No Abstract]   [Full Text] [Related]  

  • 11. Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction.
    Kojima S; Matsuyama T; Sato T; Horibe K; Konishi S; Tsuchida M; Hayashi Y; Kigasawa H; Akiyama Y; Okamura J
    Blood; 1990 Dec; 76(11):2348-53. PubMed ID: 2147864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro cell growth in neonates with Down's syndrome and transient myeloproliferative disorder.
    Denegri JF; Rogers PC; Chan KW; Sadoway J; Thomas JW
    Blood; 1981 Oct; 58(4):675-7. PubMed ID: 6456025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis.
    Fong CT; Brodeur GM
    Cancer Genet Cytogenet; 1987 Sep; 28(1):55-76. PubMed ID: 2955886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of decreased T-cell-mediated natural cytotoxicity and interferon production in Down's syndrome.
    Nair MP; Schwartz SA
    Clin Immunol Immunopathol; 1984 Dec; 33(3):412-24. PubMed ID: 6209046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related expansion of functionally inefficient cells with markers of natural killer activity in Down's syndrome.
    Cossarizza A; Ortolani C; Forti E; Montagnani G; Paganelli R; Zannotti M; Marini M; Monti D; Franceschi C
    Blood; 1991 Mar; 77(6):1263-70. PubMed ID: 1825795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of blood cell populations, plasma zinc and natural killer cell activity in young children with Down's syndrome.
    Noble RL; Warren RP
    J Ment Defic Res; 1988 Jun; 32 ( Pt 3)():193-201. PubMed ID: 2971114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.
    Creutzig U; Ritter J; Vormoor J; Ludwig WD; Niemeyer C; Reinisch I; Stollmann-Gibbels B; Zimmermann M; Harbott J
    Leukemia; 1996 Nov; 10(11):1677-86. PubMed ID: 8892666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Six cases of Down's syndrome with leukemia-like blood picture--leukemia and transient abnormal myelopoiesis (TAM)-- (author's transl)].
    Shinbo T; Nagao T; Kimura S; Misugi K
    Rinsho Ketsueki; 1977 Feb; 18(2):99-109. PubMed ID: 140254
    [No Abstract]   [Full Text] [Related]  

  • 19. Leucocyte ultrastructure and folate metabolism in Down's syndrome.
    Gericke GS; Hesseling PB; Brink S; Tiedt FC
    S Afr Med J; 1977 Mar; 51(12):369-74. PubMed ID: 139696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down's syndrome and acute leukaemia.
    Lancet; 1972 Dec; 2(7788):1187. PubMed ID: 4117604
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.